DUVAX Vaccine for Alzheimer's Disease
(DU-PRISM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new vaccine called DUVAX to determine its safety and ability to help the body produce antibodies against proteins linked to Alzheimer's disease. Participants will receive injections of either the DUVAX vaccine at varying doses or a placebo (a harmless substance resembling the vaccine) for comparison. The main goal is to assess vaccine tolerance and whether it triggers an immune response. Healthy adults with no significant health issues and within a specific weight range may be suitable for this study. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Do I need to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you use immunosuppressive agents or chronic anticoagulants.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Studies have shown that similar vaccines targeting amyloid-beta, like Nuravax, have been safe in early trials and have triggered a good immune response. DUVAX is currently in the early stages of testing, so researchers are still determining its safety for people. This phase focuses on ensuring the treatment does not cause serious side effects. As a new vaccine, DUVAX hasn't been tested for age-related conditions other than Alzheimer's. Currently, specific data on DUVAX's safety in humans is unavailable. However, researchers are closely monitoring its effects to ensure it is well-tolerated.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about DUVAX because it represents a novel approach to treating Alzheimer's disease. Unlike current treatments, which typically focus on managing symptoms or slowing disease progression, DUVAX is designed as a vaccine that aims to stimulate the body's immune response against the disease itself. The treatment involves intramuscular injections of either 200 µg or 400 µg of DUVAX formulated with an adjuvant, which is meant to enhance the immune reaction. This mechanism of action is quite different from existing Alzheimer's medications, which primarily target neurotransmitter activity. If successful, DUVAX could offer a proactive way to combat Alzheimer's, potentially altering the disease course rather than just managing symptoms.
What evidence suggests that the DUVAX vaccine might be an effective treatment for Alzheimer's?
Research shows that the DUVAX vaccine, which participants in this trial may receive, is designed to help the body produce antibodies against proteins linked to Alzheimer's disease. The vaccine targets two specific proteins, Aβ and tau, believed to contribute to the disease's progression. In animal studies, similar vaccines successfully triggered immune responses against these proteins. Early results suggest this method might help reduce the build-up of these proteins, potentially slowing the disease's progress. However, limited information from human studies exists, and more research is needed to determine its effectiveness in people.12367
Who Is on the Research Team?
Roman Kniazev
Principal Investigator
Nuravax, Inc.
Anahit Ghochikyan, PhD
Principal Investigator
IMM
David Cribbs, PhD
Principal Investigator
Nuravax, Inc.
Are You a Good Fit for This Trial?
This trial is for healthy adults who are at risk of developing Alzheimer's disease but currently show no symptoms. Participants should not have any history of severe allergic reactions to vaccines or ingredients in DUVAX.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive three intramuscular injections of DUVAX or placebo at Weeks 0, 4, and 22
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DUVAX
Trial Overview
The study tests the safety and immune response to DUVAX, a vaccine aimed at preventing Alzheimer's. Participants will receive either the vaccine at two different doses (200 µg or 400 µg) or a placebo via injection, randomly assigned.
How Is the Trial Designed?
Participants receive three intramuscular injections of DUVAX 400 µg formulated with Adjuvant at Weeks 0, 4, and 22.
Participants receive three intramuscular injections of DUVAX 200 µg formulated with Adjuvant at Weeks 0, 4, and 22.
Participants receive three intramuscular injections of placebo (adjuvant formulation without active antigen) at Weeks 0, 4, and 22.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nuravax, Inc.
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
Institute for Molecular Medicine
Collaborator
Citations
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting ...
The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.
2.
alzdiscovery.org
alzdiscovery.org/uploads/cognitive_vitality_media/Duvax_%28drug_in_development%29.pdf1 Last updated on February 18, 2025 Cognitive Vitality ...
Aging and related health concerns: No studies have tested Duvax for age-related conditions aside from Alzheimer's disease. Safety: In mice, AV-1959R/D and ...
Project Details
Project Narrative Phase 1 (R43) of this project aims to assess the overall safety and determine the optimal dose range of the Duvax vaccine targeting Aβ/tau in ...
Nuravax & IMM to Present Alzheimer's Vaccine Data at ...
"Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer's vaccine AV-1959R at CTAD 2025.
DUVAX Vaccine for Alzheimer's Disease · Info for Participants
The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.
6.
insideprecisionmedicine.com
insideprecisionmedicine.com/topics/precision-medicine/nuravax-alzheimers-vaccine-to-amyloid-beta-is-safe-immunogenic-in-phase-1/Nuravax Alzheimer's Vaccine to Amyloid-Beta Is Safe, ...
Nuravax's Alzheimer's disease mRNA vaccine AV-1959R for amyloid beta recently passed its first clinical milestone: the vaccine was deemed safe and triggered ...
7.
prnewswire.com
prnewswire.com/news-releases/breakthrough-alzheimers-vaccine-duvax-secures-3-million-nih-grant-to-launch-us-clinical-trials-302446078.htmlBreakthrough Alzheimer's Vaccine Duvax Secures $3 ...
The grant, awarded through NIH's highly competitive SBIR Fast-Track program, will fund a critical milestone in the clinical validation of Duvax.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.